MedTrace Logo

Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis

NCT01826201 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2014-12-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether MOL4239 is effective in adult subjects with mild to moderate plaque psoriasis by comparing two target lesions in which each subject will apply MOL4239 ointment to one target lesion and placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days.

Conditions

Interventions

DRUG

MOL4239

10% MOL4239 ointment to one target lesion twice a day for 28.5 consecutive days

DRUG

Placebo

placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days

Sponsors & Collaborators

  • Moleculin, LLC

    lead INDUSTRY

Principal Investigators

  • Eduardo Tschen, MD · Academic Dermatology Associates

  • Javier Alonso-Llamazares, MD · International Dermatology Research, Inc.

  • Steven Kempers, MD · Minnesota Clinical Study Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
72 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01826201 on ClinicalTrials.gov